Key Points
- David Linetsky sold 8,332 shares of Phreesia on April 10 at an average price of $8.07 (about $67,239) under a pre-arranged Rule 10b5‑1 plan to cover tax withholding from vested equity, reducing his stake by 3.59% to 224,056 shares.
- Phreesia reported Q1 EPS of $0.02 versus analyst expectations of $0.07 (an EPS miss), while revenue was $127.07 million, up 15.9% year‑over‑year and roughly in line with estimates.
- Analysts have trimmed price targets (consensus target now $20.82) and issued mixed ratings, though the consensus is a Moderate Buy; the stock is trading near $8.55, close to its one‑year low of $7.77 versus a high of $32.76.
Phreesia, Inc. (NYSE:PHR - Get Free Report) insider David Linetsky sold 8,332 shares of the company's stock in a transaction on Friday, April 10th. The stock was sold at an average price of $8.07, for a total transaction of $67,239.24. Following the transaction, the insider owned 224,056 shares of the company's stock, valued at approximately $1,808,131.92. The trade was a 3.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
David Linetsky also recently made the following trade(s):
- On Wednesday, March 18th, David Linetsky sold 107 shares of Phreesia stock. The stock was sold at an average price of $11.06, for a total transaction of $1,183.42.
- On Friday, January 16th, David Linetsky sold 6,038 shares of Phreesia stock. The stock was sold at an average price of $16.36, for a total transaction of $98,781.68.
- On Thursday, January 15th, David Linetsky sold 1,743 shares of Phreesia stock. The stock was sold at an average price of $16.38, for a total transaction of $28,550.34.
Phreesia Stock Up 6.1%
Shares of Phreesia stock opened at $8.55 on Tuesday. The company has a market cap of $519.77 million, a P/E ratio of 285.13 and a beta of 0.86. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.53 and a current ratio of 1.53. Phreesia, Inc. has a one year low of $7.77 and a one year high of $32.76. The firm has a fifty day moving average of $11.23 and a two-hundred day moving average of $16.60.
Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings data on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.07 by ($0.05). Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The firm had revenue of $127.07 million for the quarter, compared to analysts' expectations of $126.75 million. During the same quarter in the previous year, the company posted ($0.11) EPS. The firm's quarterly revenue was up 15.9% compared to the same quarter last year. On average, analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on the stock. Stephens lowered their price target on shares of Phreesia from $32.00 to $20.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 31st. Wells Fargo & Company lowered their price target on shares of Phreesia from $30.00 to $25.00 and set an "overweight" rating on the stock in a research note on Thursday, March 26th. Mizuho lowered their price target on shares of Phreesia from $22.00 to $19.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 24th. Canaccord Genuity Group lowered their price target on shares of Phreesia from $33.00 to $22.00 and set a "buy" rating on the stock in a research note on Tuesday, March 31st. Finally, Robert W. Baird reaffirmed a "neutral" rating and set a $10.00 price target (down from $25.00) on shares of Phreesia in a research note on Tuesday, March 31st. Twelve analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $20.82.
View Our Latest Analysis on Phreesia
Institutional Investors Weigh In On Phreesia
A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Phreesia by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 5,744,326 shares of the company's stock valued at $97,194,000 after acquiring an additional 39,540 shares during the last quarter. Greenhouse Funds LLLP grew its stake in Phreesia by 16.8% in the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company's stock valued at $91,317,000 after acquiring an additional 557,265 shares during the last quarter. Granahan Investment Management LLC grew its stake in Phreesia by 73.8% in the 4th quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company's stock valued at $40,601,000 after acquiring an additional 1,018,987 shares during the last quarter. Franklin Resources Inc. grew its stake in Phreesia by 28.8% in the 4th quarter. Franklin Resources Inc. now owns 2,000,082 shares of the company's stock valued at $33,841,000 after acquiring an additional 446,890 shares during the last quarter. Finally, Nuveen LLC grew its stake in Phreesia by 12.7% in the 4th quarter. Nuveen LLC now owns 1,875,725 shares of the company's stock valued at $31,737,000 after acquiring an additional 211,262 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.
About Phreesia
(
Get Free Report)
Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.
Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
